Company Overview of HemoShear Therapeutics, LLC
HemoShear Therapeutics, LLC discovers novel biological targets and drugs to treat a range of metabolic disorders that have significant unmet patient need. It develops and validates REVEAL-Tx, a transformational and proprietary drug discovery platform that provides unprecedented insights into human disease biology by replicating human disease. The company focuses on the family of inherited disorders called Organic Acidemias with known mutations and strong clinical hypotheses for drug targets; and on drug discovery in Nonalcoholic Steatohepatitis, a serious, chronic, and progressive liver disease. HemoShear Therapeutics, LLC was formerly known as HemoShear, LLC and changed its name to HemoShea...
501 Locust Avenue
Charlottesville, VA 22902
Founded in 2008
Key Executives for HemoShear Therapeutics, LLC
Chairman and Chief Executive Officer
Co-Founder and Chief Scientific Officer
Co-Founder, Vice President of Research & Development and Director
Vice President of Operations
General Counsel and Director
Compensation as of Fiscal Year 2016.
HemoShear Therapeutics, LLC Key Developments
HemoShear Therapeutics Appoints H. Thomas Watkins to its Board of Directors
Nov 30 15
HemoShear Therapeutics reported the appointment of H. Thomas Watkins to its Board of Directors. Watkins is the former president and chief executive officer of Human Genome Sciences and also served as the chairman of the Biotechnology Industry Organization.
HemoShear Names Vincent E. Aurentz as President
Jun 11 15
HemoShear announced that Vincent E. Aurentz, Chief Business Officer, has been named President of HemoShear. Mr. Aurentz will be responsible for leading HemoShear's scientific and business development strategies, as well as public relations and marketing, in addition to his existing business development responsibilities. He will continue to report directly to CEO and Chairman Jim Powers, and will also join HemoShear's Board of Managers. Mr. Aurentz's appointment will utilize his more than 25 years of experience in the pharmaceutical and biotech industry as an entrepreneur and pharmaceutical R&D executive. He spent almost nine years with Merck KGaA and Merck Serono where he was Executive Vice President, Portfolio Development and member of the Executive Management Board as well as Head of Global Business Development. He was also recently Executive Vice President at Quintiles.
HemoShear Completes First Phase of Development of Novel Cancer Drug Discovery Platform
Oct 9 14
HemoShear announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations. Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs. Using their new platform, HemoShear was able to successfully replicate human therapeutic response to Cisplatin, a drug approved to treat non-small cell lung carcinomoa, at a therapeutically-relevant concentration. Similarly, HemoShear evaluated two other drugs currently in clinical studies and confirmed a therapeutic response. When evaluated in traditional cell culture systems and mouse studies, the same dose of Cisplatin does not show a response. HemoShear's findings reinforce the need to test cancer drug candidates under more human-relevant tumor conditions. HemoShear's translational tissue systems apply physiological blood flow characteristics to human tissue to restore its in vivo biology, using material from HemoShear's biorepository and interpreting data with cutting edge computational analytics. In phase I of the NCI-funded program, HemoShear demonstrated that NSCLC tumor structure, biology, and molecular signaling pathways are restored in the HemoShear platform.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 3, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries